Skip to main content

You are here

Vishnu Chaturvedi, Ph.D.

Vishnu Chaturvedi, Ph.D.

Director, Mycology Special Services
Ph.D., University of Delhi, Delhi, India
Postdoctoral training: Texas Tech University Health Sciences Center, Lubbock, TX
Postdoctoral training: University of Cincinnati School of Medicine, Cincinnati, OH
518-474-4177

Research Interests

Genomics – We are working on the whole-genome sequencing (WGS) methods for a number of fungal pathogens. The approaches are based on short-read (Illumina) and long-read (PacBio and Oxford Nanopore) sequencing technologies. The corresponding bioinformatics workflow is also being modified. The long-term goal is to validate and implement CLIA-compliant WGS applications for a medical mycology laboratory.

Molecular epidemiology – We use molecular epidemiology tools for rapid outbreak investigations, characterization of unknown etiologic agents and correlation of geography with pathogen virulence. We aim to successfully bridge the gap between basic research and translational science for improved infectious disease diagnosis.

Microbial Pathogenic Mechanisms - We pioneered the use of genetic and genomic approaches to dissect pathogenic mechanisms used by human and bat white-nose syndrome fungal pathogens. Our focus remains on the exquisite interplay of fungal stress response, metabolic profiles, and virulence.

Antimicrobial standardization & discovery – Collaborative research has resulted in development of several rapid and sensitive methods for susceptibility testing of antifungals alone and in combination. In addition, Candida and Cryptococcus prolyl isomerases were identified as unique antifungal drug targets. Our current focus is on the WGS-enabled testing for antimicrobial resistance in emerging multidrug-resistant pathogen Candida auris.

Select Publications

Kaplan M, Zhu Y, Kus JV, McTaggart L, Chaturvedi V, Chaturvedi S.
Development of a Duplex Real-Time PCR Assay for the Differentiation of Blastomyces dermatitidis and Blastomyces gilchristii and a Retrospective Analysis of Culture and Primary Specimens from Blastomycosis Cases from New York (2005 to 2019).
J Clin Microbiol.
(2021)
59
(3):
e02078-20.
DOI: 10.1128/JCM.02078-20
Zhu Y, O'Brien B, Leach L, Clarke A, Bates M, Adams E, Ostrowsky B, Quinn M,Dufort E, Southwick K, Erazo R, Haley VB, Bucher C, Chaturvedi V, Limberger RJ, Blog D, Lutterloh E, Chaturvedi S.
Laboratory Analysis of an Outbreak of Candida auris in New York from 2016 to 2018: Impact and Lessons Learned.
J Clin Microbiol.
(2020)
58
(4):
e01503-19.
DOI: doi: 10.1128/JCM.01503-19
Chaturvedi V, Linhardt RJ, Papon N.
Candida auris Mannans and Pathogen-Host Interplay.
Trends Microbiol.
(2020)
28
(12):
954-956.
DOI: 10.1016/j.tim.2020.10.003
Zhu Y, Kilburn S, Kapoor M, Chaturvedi S, Shaw KJ, Chaturvedi V.
In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak.
Antimicrob Agents Chemother.
(2020)
64
(11):
e01124-20.
DOI: 10.1128/AAC.01124-20
Ren P, Rajkumar SS, Zhang T, Sui H, Masters PS, Martinkova N, Kubátová A, Pikula J, Chaturvedi S, Chaturvedi V.
A common partitivirus infection in United States and Czech Republic isolates of bat white-nose syndrome fungal pathogen Pseudogymnoascus destructans.
Sci Rep.
(2020)
10
(1):
13893.
DOI: 1038/s41598-020-70375-6